Ceapro Inc V.CZO

New Press Release - Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update

– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,000 in Q1 2023– Announcedapproval by...read article.

[lscfa]

Drunken sailor spending....     Revenues Gross profit Gross margin Cash flow ops R&D G&A incl legal Legal fees Q1 24 2,773,788 1,218,406 43.9%

[lscfa]

Germany sales permanently lower?        US Germany China Other Canada Total Q1 24 2,149,017 566,361 0 50,186 8,224 2

[prophetoffactz]

There's so much they aren't saying in this news release. Maybe more detail once the merger closes. What about the dry powder with Symrise and the malted avenanthramide evaluation? What is the plan for the chewy product. When do they expect a PGX deal now that the 5X scale-up appears almost complete and it was to provide material for a potential partner, etc. 

[lscfa]

Base biz barely cash flow positive   CFO b/f legal & R&D   439,733 Q1 24 (361,227) Q4 23 744,074 Q3 23 265,473 Q2 23 1,079,425 Q1

[Tencents]

It would seem czo will have a cash crunch in the next 6 months - based on current flows and probable merger integration / redundancy costs - cash less than 5 m compared to 12 m q2 2023  while its previously announced that base business records have started , delivery dates are not indictated but seems it could be later 2024 or 2025